-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Benzinga·10/15/2026 10:16:01
Diffusion vocale
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.